Novan Announces Promising Clinical Results with SB414
August 20, 2018 06:30 ET
|
Novan, Inc.
In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant biomarker changes suggesting a topical nitric oxide...
Novan Provides Update on SB414 Inflammatory Skin Disease Development Program
May 15, 2018 08:10 ET
|
Novan, Inc.
SB414 – Nitric Oxide-Releasing Cream – Safe and Well-Tolerated in Psoriasis Phase 1b Trial Preclinical Data with SB414 Targeting Key Inflammatory Cytokines IL-4 and IL-13 in Atopic Dermatitis to be...
Novan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414
December 05, 2017 08:35 ET
|
Novan, Inc.
MORRISVILLE, N.C., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 1b clinical...
Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
April 27, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing...